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Abstract
Vaccinia is the model virus used to study the lifecycle of poxviruses, large DNA viruses
that include agents of human disease such as smallpox and monkeypox. Unusual for
DNA viruses, poxviruses replicate in the cytoplasm of the cell, autonomous from the
nucleus. Because of this autonomy, the virus encodes a large number of genes devoted
to replication and morphogenesis. The initial steps of morphogenesis, known as
membrane biogenesis, remain unclear. The viral membrane is thought to originate from
the endoplasmic reticulum; however, how the membrane is diverted from that organelle
is currently not known. Various viral proteins have been identified as being vital to this
process. We have been developing genetic tools to study the A30.5 and L2 proteins,
two of the regulatory proteins that reside in the ER membrane. Although these proteins
are thought to be essential for membrane biogenesis, their mode of action remains
unknown. In order to dissect their mode of action, identify functional domains, and
investigate protein-protein interactions, we have generated an L2 complementing cell
line (CV1:L2HA) and an L2 deletion virus (vΔL2) as well as two inducible A30.5 viruses
(vind3XFA30.5; vindA30.5V5). With these reagents, we will assess the full range of
phenotypes observed when these proteins are absent. vΔL2 is severely compromised in
two different non-complementing cell lines. For structure/function analysis, we will
perform complementation analyses with a variety of mutated alleles to identify key
domains within L2. The Tet inducible A30.5 viruses, in contrast, are only modestly
impaired, with viral yield reduced 3-16 fold in the absence of inducer. The inducible
viruses are somewhat leaky, with 2-11% of A30.5 expression under non-induced
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conditions. To determine whether this leakiness is the cause of the weak phenotype of
the vindA30.5 viruses, we are now generating a complementing CV1:3XFLAGA30.5 cell
line that will be used to generate a vΔA30.5 deletion virus. We also investigated some
structural aspects of A30.5 and L2, including covalent dimerization and phosphorylation
status. From our study, neither protein appears to form a covalent dimer. We concluded
that A30.5 is phosphorylated.
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Chapter 1: Introduction
Vaccinia virus is the prototypical virus used to study the lifecycle of poxviruses, a
class of large DNA viruses that includes agents of human diseases including smallpox
(variola) and monkeypox. Poxviruses have been dated back to antiquity, with evidence of
infection found in Egyptian mummies as far back as 1500 BC.1, 2 Smallpox become a
worldwide epidemic, spreading from Europe to the Far East, and later to the Americas as
the conquest of the New World began.1, 2 It was used as an agent of biowarfare against
the Native Americans as a means for colonization.1 Variola became the first virus to be
prevented by vaccination, famously advocated by Lady Montague.1, 2 The procedure, more
accurately referred to as variolation, was carried out by rubbing dried pustules from
infected individuals into open wounds of the uninfected patients. While this method had
some success, many inoculated caught the disease and died. A revelation came when
Edward Jenner noticed pox-like pustules on the hands of milk maids, who were immune
to variola.1, 2 Jenner surmised that the disease that they were contracting from working
with cows infected with cowpox were contributing to the immunity in the milk maids. Jenner
performed several trials of inoculating children with cowpox, and then exposing them to
smallpox.1, 2 His trials were often successful, and a new age of vaccination had begun.
The term vaccine is derived from the origin of the inoculum from cows, Latin for “vacca”.
It was later realized that the virus that was being used to vaccinate patients was not
cowpox, or had become something different. The name given to this new virus was
vaccinia.1, 2 Vaccinia remained the agent used to vaccinate individuals until the eradication
of smallpox as a natural pathogen in 1980, due to massive worldwide vaccination efforts
by the World Health organization.1, 2 The last recorded case of natural smallpox infection
was seen in 1978.1 Under much controversy, reserves of the virus were kept, and remain
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so, by the United States and the USSR. After the fall of the USSR, worries over who may
have access to the stock sprung up, as did fears of its use as an agent of biowarfare
against a generation that were no longer immune to the virus.1, 2 Many believe that the
existence of the virus serves no scientific benefit, only a hazard for the reemergence of
one of the most deadly and pathogenic diseases in recorded human history. Proponents
of keeping the stock claim that much remains to be learned from variola including improved
therapeutic developments and a furthering our understanding of viral pathogenesis.
Although this virus has been known to humans for thousands of years, many aspects of
the lifecycle remain a mystery.
Unique to DNA viruses of mammalian cells, poxviruses replicate in the cytoplasm,
autonomous from the nucleus, which means that the virus must encode a large number
of genes that are devoted to the processes of transcription, replication, and
morphogenesis (figure 1). The vaccinia virus has a large genome compared to most
viruses, almost 200 kb, which encodes approximately 200 genes. The vast number of
genes are highly regulated to coordinate these complex functions. The major steps that
occur during the pox lifecycle include binding and entry, early gene expression, uncoating,
replication, intermediate and late gene expression, morphogenesis, and egress from the
cell.
Virion and Genome Structure
Vaccina virus is an enveloped virus, and is sometimes wrapped in a second
membrane derived from the Golgi of the cell. Virions with a single membrane are referred
to as mature virions (MV); virons with a double membrane are referred to as enveloped
virions (EV). The vaccinia virion is rather large compared to most mammalian viruses, and
is around 200nm in diameter and 300 nm in length.3 Its core is complex and forms a
dumbbell shape with aggregates of heterogeneous material called lateral bodies.3
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Vaccinia virions carry a single copy of its large 200kb genome, which is linear and double
stranded.
Binding and Entry
The first step in the lifecycle of the poxvirus is entry into the cell. Several
mechanisms of entry have been proposed and different mechanisms are used whether
the entering virus is a mature virions or an enveloped virion . The exact receptor that
mediates binding and entry has not been identified, although it is thought to be facilitated
by glycosaminoglycans (GAGs).3, 4 The A27 protein has a domain which binds to GAGs,
and when soluble form is used to treat the cells before inoculation, the cells become much
more resistant to infections.4

The surface proteins of MV’s and EV’s differ and the

efficiency of entry is not the same, suggesting that there is not a single receptor that
mediates binding.3 Entry of MV has been shown to be facilitated by the fusing of its
membrane with the plasma membrane in a pH neutral manner.3, 5 Other evidence has
shown MV’s being found cytoplasmic vesicles, suggesting an actin mediated
internalization process, possibly macropinocytosis.3, 6 In such a case, acidification of the
endosome would occur, and inhibitors of this process have shown to inhibit entry.3, 7 The
differences in mechanism of entry could depend on the cell type or the receptor to which
the virion binds. In contrast to the entry of an MV, EV must have its outer membrane
removed prior to the entry of the virion, as the fusion-entry proteins are located on the MV
membrane.3, 8
Expression Cascade
The gene expression program of the poxvirus lifecycle is tightly regulated in a
temporal manner. After entry into the cell, the virion will immediately start to produce early
mRNA products from its core which is mediated by a multisubunit DNA-dependent RNA
polymerase and stage specific transcription factors.3, 9 The core of the virion contains a

3

transcriptional system that is capable of producing methylated, capped, and
polyadenylated mRNA transcripts.3,

10

Packed within the core are several enzymes

including DNA dependent RNA polymerase, early transcription factors, methylating
enzymes, polyA polymerase, and topoisomerase.3, 10, 11 Some of the early gene products
include a DNA polymerase and the entire repertoire of viral replication proteins,
intermediate transcription factors, RNA polymerase, growth factors such as the vaccinia
growth factor, a homolog of cellular EGF, and immune defense molecules, including K3L
and E3L, inhibitors of PKR, a cellular sensor of double stranded RNA.3,

12, 13

The

expression system of the poxvirus is sequential, following a cascade mechanism where
early gene products act as transcription factors for intermediate genes, and intermediate
products act as transcription factors for late genes. Early gene expression halts following
the uncoating of the virion, along with the degradation of some of the early mRNAs,
possibly facilitated by viral proteins.3, 14 Uncoating is thought to occur when a nucleoprotein
complex exits the core wall in a proteasome dependent manner.3,

15

This process is

dependent on RNA and protein synthesis.15 Once the core is dismantled, a rise in the
levels of intermediate gene products can be seen, and the process of genome replication
can begin.3 Lastly, as triggered by intermediate gene products, late genes are expressed
and persist until the end of the lifecycle. These late gene products include components
needed for morphogenesis and the structural proteins and enzymes that will comprise the
core of progeny virion.3
Genome Replication
Unique to DNA viruses of mammalian cells, vaccinia replicates in the cytoplasm of
the cell, autonomous from the nucleus. Because of this, the virus encodes a large number
of viral proteins dedicated to DNA replication, independent of the host replication
machinery. The essential proteins for replication include the E9 DNA polymerase, B1
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kinase, the D5 primase/ATPase, I3 single-strand DNA binding protein, A20 component of
the processivity factor, D4R uracil DNA glycosylase and component of the processivity
factor, and the abundant H5 phosphoprotein.16-18 Other proteins important in this process
include a DNA ligase and a Fen1 like nuclease.3, 16 Replication occurs within dedicated
foci in the cytoplasm called replication factories from which cellular organelles are
exluded.19 Replication begins at approximately 3 hours post infection, and peaks at 10-12
hours.16, 17, 19 The genome of vaccinia is packaged as a monomer and replication begins
when a nick is introduced.3, 20 The nick provides a primer terminus for the elongation of
the genome by the viral polymerase.3,

17, 20

One model of replication includes the

polymerase copying both strands of the duplex in a leading strand only model of
replication, however this model is still being contested. The result is the formation of tailto-tail dimers that are resolved by a viral resolvase.3, 17, 20
Morphogenesis
After genome replication and the production of late gene products, which include
late enzymes and structural proteins, comes the process of morphogenesis, where
progeny virions are formed (figure 2).21 The process of morphogenesis includes the
diversion of a crescent membrane from the endoplasmic reticulum (ER), crescent growth
around a non-membrane bound organelle referred to as viroplasm which contains the
proteins needed to form immature virions (IV).21 Encapsidation of the viroplasm and
genome to form immature virions with nucleoid (IVN), and finally, a proteolytic step that
results in the formation of mature virions (MV).21 Some fraction of MV’s will acquire a
double membrane derived from the Golgi.21
The origin of the crescent had been disputed for many years. Early descriptions
concluded that the crescents consisted of a single bilayer with a layer of spicules.21, 22 The
formation of these crescents were thought to be connected to the replication factories and
had no connection to any cellular organelle.21,

23

The de novo model of membrane
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formation was problematic because the standard concept is that membranes only
originate from existing membranes.21, 22

23

Another issue with this theory was the fact that

crescent membranes would have exposed hydrophobic chains exposed to the aqueous
cytoplasm, which would be energetically unfavorable.21
Further studies suggested that the single membrane bilayer might actually be tightly
apposed bilayers derived from the cisternae of organelle membranes.21 Several models
were proposed as to how a bilayer could be functioning to form a mature virion. The
previously described spicule on the edge of the crescents is formed from a lattice of the
viral protein D13.21, 24 The D13 lattice can be disrupted with the antibiotic rifampicin, and
consequently can be used to block morphogenesis and to separate the spicule from the
crescents.21, 24 Imaging studies using rifampicin reversal have shown clear evidence that
the crescents are most likely to be formed from a single bilayer.21
Even though the structure of the membrane was resolved, its origin was not. The
de novo origin was still disputed, with some evidence showing no continuity with any
cellular membrane, and others with some evidence of association.21 The membrane of the
mature virion showed little similarities to any cellular membrane.21 Although none of the
mature virion membrane proteins are glycosylated, it was shown that the membrane
proteins A14 and A17 were co-translationally inserted in the membrane of the ER,
suggesting that the ER could be a site of origin.21, 25 An idea was proposed that the origin
of the crescents would involve COPI or COPII trafficking pathways, however inhibition
studies have shown this not to be the case.21, 26, 27 The mechanism of crescent diversion
remains a mystery.
The next step in morphogenesis is the process of immature virion formation.
Growing crescents are known to associate with the viroplasm either through proteinprotein or lipid-protein interactions.21 The E6 core protein is thought to play a role in
crescent association; knockout studies reveal large accumulations of crescents that do
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not take up viroplasm.28 As the crescents grow, by an unknown mechanism, they begin to
engulf sections of the viroplasm, until they form a fully enclosed core surrounded by a
single membrane.21 A common theme throughout morphogenesis is the F10 kinase acting
a regulator, as is true in the process of immature virion formation, known to be essential
to the stability of the virosome.28, 29 F10 is responsible for the phosphorylation of several
proteins in a seven protein multimeric complex which is comprised of A15, A30, G7, D2,
D3, J1.21, 29 This complex, resident in the viroplasm, has been shown to be essential to the
formation of the immature virion, as any knockout of one of these proteins results in
destabilization of the viroplasm.21, 28
The next transition is from immature virions to immature virions with a nucleoid,
otherwise known as genome encapsidation. Encapsidation appears to be a distinct
process, unrelated to the filling of the core with cytoplasmic proteins.21 Much remains to
be discovered about the actual mechanism of encapsidation, for instance the closing of
the membrane. Through imaging studies, it appears that there is a large population of
immature virions with a nucleoid, suggesting that genome encapsidation is likely to occur
before the complete closure of the membrane, although other theories have been
suggested.21, 29 Two proteins have been identified as essential for encapsidation, A32, a
pumping ATPase, and I6, a telomere binding protein. A32 has been linked the the
encapsulation of the viral genome, independent of the loading of core proteins.30 I6 is
thought to bind to telomeres of mature genomes which assists in encapsulation.31
The final step in the formation of the mature virion is proteolytic processing where
several of the core and membrane proteins are cleaved by the I7 protease.32 The transition
involves a drastic change from a spherical (ovoid) to a barrel shaped particle. The
transition involves four main processes: transcriptional apparatus assembly, restructuring
of the virions surface including the loss of D13, the proteolysis of core and membrane
bound proteins, and the movement of the virion away from the site of assembly.21 As
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mentioned before, the movement of the virion can also involve a wrapping step through
the Golgi.
Regulatory Proteins of Membrane Biogenesis
The focus of this thesis will be on membrane biogenesis and will highlight the
methods used to study the structural and functional aspects of two proteins, L2 and A30.5,
key proteins in this process.
As mentioned before, the F10 kinase is a major regulator of morphogenesis. In its
absence, there is a null phenotype; morphogenesis does not occur; specifically membrane
biogenesis and viroplasm accumulation are inhibited.

27, 33

In addition to the F10 kinase,

five regulatory proteins have been identified that are important to biogenesis including A6,
A11, A30.5, H7, and L2 (figure 3).27 When repressed, these five proteins show a similar
phenotype: large electron-dense virosome accumulation surrounded by short crescent
membranes at the periphery.27 L2 and A30.5 are associated with the membrane of the
ER, and the other three proteins are thought to interact in a complex on the outer surface
of the ER.34 The exact function of each of these proteins remains a mystery, as does the
role of the complex as a whole. Individual analyses of these proteins are needed to gain
structural and functional information and to determine how they contribute to the process
of membrane biogenesis. Here, we will focus on the methods used to study the L2 and
A30.5 proteins and analysis of interactions, localization, and post-translational
modification.
L2 and A30.5 are unique among the regulatory proteins in that they are membrane
bound in the ER, however they do not get incorporated into the membrane of the mature
virion.34 L2’s C-terminus is found in the lumen of the ER and its N-terminus extends into
the cytoplasm.35 A30.5, a protein identified in a screen for L2 interacting proteins, forms a
hairpin with both termini in the cytoplasm.35 L2 and A30.5 are known to interact, at least
indirectly.

34

L2 is expressed early in the lifecycle, which is unusual for proteins involved
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in morphogenesis, as opposed to A30.5 which is expressed late.34, 36 L2 is not thought to
be modified post-translationally, while A30.5 has not been studied.27
In order to study L2 and A30.5 we generated deletion or inducible mutants. For L2
we used an L2 complementing cell line (CV1:L2HA) to generate an L2 deletion virus
(vΔL2). For A30.5 we created two inducible viruses (vind3XFlagA30.5; vindA30.5V5),
however because these viruses were leaky, we created a complementing cell line
(CV1:3XFA30.5) in order to generate an A30.5 deletion virus. The validation and
phenotypes of these recombinants will be presented here.
Using these genetic tools, we will confirm that L2 is not phosphorylated in vivo,
and test the phosphorylation status of A30.5. We will also investigate if L2 or A30.5 form
covalent dimers.
Chapter 2: Materials and Methods
Materials, Cells, and Viruses
African green monkey kidney BSC40 cells and human TK- 143B cells were cultured in
Dulbecco's modified Eagle medium (DMEM) containing 5% fetal calf serum (Invitrogen,
Carlsbad, CA) at 37°C in the presence of 5% CO2; CV1-L2, CV1-CAT, and HeLa cells
were cultured similarly except that the medium contained 10% FBS. Viral stocks, WR
strain of vaccinia virus, were prepared by ultracentrifugation of cytoplasmic lysates
through 36% sucrose; titration was performed on confluent monolayers of BSC40 cells,
which were fixed and stained with 0.1% crystal violet in 3.7% formaldehyde at 48 hpi.
Restriction endonucleases, T4 DNA ligase, and calf intestinal alkaline phosphatase (CIP)
were purchased from Roche Applied Sciences (Indianapolis, IN). Geneticin (G418 sulfate)
and SuperSignal West Pico chemiluminescence substrate was purchased from
ThermoFischer (Waltham, MA). Lipofectamine 2000, monoclonal V5 antibody, protein
molecular weight marker SeeBlue Plus2, and lambda DNA/HindIII marker were purchased
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from Invitrogen (Carlsbad, CA). L-methionine free DMEM media was purchased from MP
Biomedicals (Solon, OH). Secondary HRP-congugated antibodies (goat anti mouse and
goat anti rabbit) was purchased from BioRad (Hercules, CA). (Sodium phosphate free
DMEM was purchased from Life Technologies (Carlsbad, CA) Monoclonal M2 Flag
antibody, and Taq polymerase were purchased from Sigma (St. Louis, MO). Monoclonal
HA antibody was purchased by Covance (Dedham, MA).
Anti-L2 antisera. Polyclonal L2 antibody was produced by Pocono Rabbit Farm &
Laboratory Inc. (Canadensis, PA).
Anti-F18 and anti-L4 antisera. The F18 gene was amplified by PCR using appropriate
primers, and an EcoRI-BamHI fragment extending from nt 3 through the rest of the gene
was cloned into a pATH3 vector. E. coli transformants containing this plasmid directed the
inducible synthesis of a 48-kDa fusion protein containing 37 kDa of E. coli TrpE and 11
kDa of F18. The L4 gene was amplified by PCR using appropriate primers and inserted
into a pUC vector; a BglII-HindIII fragment extending from nt 115 of the L4 gene through
the stop codon into adjacent vector sequences was inserted into a pATH11 vector
previously digested with BamHI and HindIII. This vector directed the inducible synthesis
of a fusion protein containing 37 kDa of the E. coli TrpE protein and 25 kDa of the L4
protein (containing all but the N-terminal 38 amino acids of the initial translation product
and all but 6 amino acids of the mature, proteolytically cleaved protein). The fusion
proteins were excised from SDS-polyacrylamide gels and used to inoculate rabbits. The
specificity of the resultant polyclonal antisera was confirmed by immunoblotting and
immunoprecipitation.37
Generation of the vΔindA30.5V5 and vΔind3xFlagA30.5 viruses
3xFlagA30.5 and A30.5 V5 were cloned into pJS4-tetR.38 The final plasmid contains two
transcriptional cassettes. One drives constitutive expression of the TET repressor (tetR),
and the other contains either the 3xFlagA30.5 or A30.5V5 ORF under the regulation of
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the TET operator and the A30.5 endogenous promoter. These two cassettes are flanked
by the left and right halves of the TK gene, which enables insertion into the genome by
homologous recombination into the TK locus. Cells were infected with WR virus at an MOI
of 0.03 and transfected with linearized plasmid, cut with ScaI. Intermediate virus was
isolated by two rounds of plaque purification on human TK- cells in the presence of BrdU
(25 µg/ml). The presence of the tagged A30.5 positive plaques were screen by PCR using
TK primers. Positively identified plaques were expanded, viral stocks were prepared, and
stocks were titrated on monolayers of BSC-40 cells.
Knockout of the endogenous A30.5 in the intermediate viruses was conducted in a threepart ligation where A30 was generated by PCR and cloned into pBSIIKS.38 A31 was
generated by PCR and cloned into pBSIIKS-A30. Finally, NEO was excised from pUCNEO and ligated into pBSIIKS-A30,A301. The plasmid was linearized with ScaI and
transfected into cells infected with intermediate virus at an MOI of 0.03. Resulting virus
underwent two rounds of selection in media containing G418 (0.6mg/mL). Virus was
expanded, purified, and titrated on monolayers of BSC40 cells in the presence of Tet (1.0
mg/mL)
Generation of the vΔL2 virus
pBSIIKSmCherry containing portions of the L1 and L2 genes that flank mCherry was
linearized and transfected into BSC-40 cells that were infected with WR to allow for
homologous recombination. Virus was plated onto induced CV1-L2 cells and plaques were
screened for fluorescence with absorbance and 594nm filtered through a Texas red cube.
Positive plaques were picked for subsequent purification. Plaques underwent four rounds
of purification in 48-well plates on induced CV1-L2 cells, plated at a density of
approximately one PFU per every three wells to maximize the possibility of isolating a
plaque that originated from a single PFU. Virus was expanded, purified, and titrated on
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monolayers of induced CV1-L2 cells. A final screen of fifty plaques from the stock by
fluorescence was performed to test for the presence of wild-type virus.
Viral yields after single replication cycle
BSC-40, CV1-L2, CV1-CAT, or HeLa cells were plated to confluency on 35-mm dishes.
For permissive condition in CV1-L2 cells, cells were treated with doxycycline for 24 h prior
to infection. Cells were infected at an MOI of 3 in DMEM without serum for 30 min innoclum
was removed and cells were fed with DMEM with serum, with respective antibiotic for
permissive conditions, Tet (1.0 m g/mL) for vind3xFlagA30.5 and vindA30.5V5 or Dox (50
ng/mL) for vΔL2. Cells were incubated at 37oC for 18 h. Cells were scraped with a rubber
policeman, harvested by centrifugation at 1700 rpm for five min, washed with PBS, and
collected again by centrifugation. Cells were freeze-thawed three times on dry ice and
were sonicated twice for 15 sec. Lysates were titrated on BSC-40 cells for wild-type,
vind3xFlagA30.5 and vindA30.5V5 with Tet (1.0 mg/mL). vΔL2 was titrated on induced
CV1-L2 cells, in the presence of Dox (50 ng/mL). Plates were fixed with crystal violet
formaldehyde solution.
Generation of CV1-3xFlagA30.5 cell line
3xFlagA30.5 was submitted to GeneArt to be codon optimized for expression in human
and primate cells. Codon optimized 3xFlagA30.5 was cloned into pcDNA5/FRT/TO
containing a CMV promoter, a Tet repressor, and a hygromycin resistance gene. The
resulting pcDNA5/FRT/TO-3xFlagA30.5 was co-transfected with pOG44, endcoding a Flp
recombinase, into CV1 cells containing a TetR gene under the selection of blasticidin with
an FRT site in a common genetic locus.39 Insertion of 3xFlagA30.5 was selected by
resistance to hygromycin. Cells were grown under the selection of hyrgromycin
(2.5mg/mL) and blasticidin (1.5 mg/mL). The resulting cells were tested for expression of
3xFlagA30.5 after induction with Dox (50 ng/mL) via western.
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Immunoblotting
Cell pellets from a confluent 35-mm dish were prepared by treatment with 20m l benzonase
buffer (50mM Tris pH 7.4, 0.1% Triton X, 100mM NaCl, 1mM MgCl2, 5 units benzonaze)
for 30 min at room temperature and prepared by adding 5ml 5x protein sample buffer with
or without b-mercaptoethanol. Polyacrylamide gels (17%) were transferred to
nitrocellulose membrane in CAPS buffer (10% methanol, 0.5M CAPS, pH 11.2)for A30.5,
L2, and A14 blots or in Tris-Glycine for I3, L4, and F18. Membranes were blocked in 5%
Sanalac milk, and incubated with antibody at 1% milk. Antibody concentrations were as
follows: M2 Flag-1:3000, V5-1:5000, L2-1:500, I3-1:3000, L4-1:500, F18-1:1500, A141:1000. Respective secondary antibodies conjugated to HRP were used at a 1:20,000.
Proteins were detected by chemiluminescence on a Gel Doc camera system and analyzed
by AlphaView software.
Plaque size determination
BSC-40 or CV1-L2 cells were plated in 60-mm dishes. Permissive CV1-L2 were treated
with Dox (50 ng/mL) for 24 h prior to infection. Twenty PFU were infected for 30 min in
DMEM without serum. Cells were fed with DMEM plus serum, plus antibiotic for permissive
dishes. Cells were incubated at 37C for 48 h and fixed with crystal violet formaldehyde
solution
Limit of detection for viral stock purity
A 1:50 dilution of the stock viral preparation was used as a template for a PCR reaction.
Primers were designed in the flanking regions of the A30 and A31 genes such that the
difference in the size of the Neo insert or endogenous A30.5 could be distinguished.
Dilutions of wild-type 1:50 solution were mixed with the stock to show the lowest
concentration at which the wild-type virus could be detected.
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Polymerase Chain Reaction
Standard PCR reactions were conducted with 0.2mM DNTP’s, 5mM primers, 1.25 units
taq, diluted in water with PCR buffer (20 mM Tris-HCl (pH 8.4), 50 mM KCl). Templates
included 10ng DNA, 1m L of a 1:50 dilution of sucrose purified stocks, or 10m L of a picked
plaque diluted in 100m L. Reactions were heated at 95C for five minutes, then cycled 25X
(95C for 1 min, 52C for 45 sec, 72C for 1:15 min) Final elongation was carried out at 72C
for 5 min and reactions were stored at 4C. Samples were resolved through a 1.5%
acrylamide gel, stained with ethidium bromine for 15 min, washed in water for 15 min, and
imaged on Gel Doc camera system.
Radiolabeling and Immunoprecipitation
BSC-40 cells were plated in 60-mm dishes to confluency. Cells were infected with mock,
wild-type virus, or vindA30.5V5 in DMEM without serum for 30 min. Cells destined for
A30.5V5 and F18 immunoprecipitation were fed in DMEM with serum, plus Tet for
A30.5V5. Cells destined for L2 immunoprecipitation were washed with methionine or
phosphate free media and fed with phosphate or methionine free media containing 5%
dialyzed media, and 100m Ci of 32P inorganic phosphate or 35S-methionine. L2 dishes were
labeled from 1-4 hpi, washed in PBS, and stored at -20C. A30.5V5 and F18 dishes were
labeled in the same manner from 4-7 hpi. Cell pellets were lysed in protein lysis buffer
(10mM NaPO4, 0.1M NaCl, 1% TritonX100, 0.1% SDS, 0.5% DOC) for 30 min. Chromatin
and cellular debris was removed by centrifugation at 13.2 RPM for 15 min at 4oC. Antiserum of F18, L2, and V5 were added to the cell lysates and were incubated on ice with
occasional mixing for 4 h. Agarose-G beads were washed and 10mg was added to each
sample and incubated at 4C for 90 min with end-over-end mixing. Beads were washed
three times for

35

S-methionine samples and four times for

32

P in protein lysis buffer.

Proteins were eluted in protein sample buffer by boiling for 5 min. Proteins were resolved
by

SDS-PAGE,

fixed,

and

dried.

35

S-methionine

samples

were

exposed

to
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autoradiography for 96 h;

32

P samples were exposed for 24 h. Typhoon phosphorimager

was used to detect radioactivity.
Statistical Analysis
Graphs were generated using SigmaPlot. CanvasDraw was used to edit raw images from
the GelDoc camera and generate figures. Band analysis was conducted with AlphaView.
DNA sequence analysis was performed with SeqBuilder 13. Lasergene Protean was used
to predict the hydrophobic regions from the primary amino acid sequences.
Primer List
Screening
L1 Forward
L3 Reverse
A30 Forward
A31 Reverse
Neo Forward
Neo Reverse
Cloning
L2 KO #1 L1
L2 KO #B
L2 KO #C
L2 KO #4 L3
A30.5 KO #1 A30

5’-GGTTATTGCTACCACGG-3’
5’-AGGCATATCACTCACCG-3’
5’-GTAGACGCGTATTGCGC-3’
5’-CGGTAGAATGCTTTGGC-3’
5’-GCCATGATGGATACTTTCTCGGCA-3’
5’-CAAGATGGATTGCACGCAGGTTC-3’

A30.5 KO #B

5’-GCCATGATGGATACTTTCTCGGCA-3’

A30.5 KO #C

5’-CAAGATGGATTGCACGCAGGTTC-3’

A30.5 KO #4 A31
pJS4-tetR A30.5 #1

5’-CCCCCTCGTTGTTTAAC-3’
5’-TCAGCTCGAGTCCCTATCAGTGATAG-3’

pJS4-tetR A30.5 #1b
pJS4-tetR A30.5 #2

5’-TCAGCTCGAGCATATGTTAAAAATGTCCG-3’
5’-GCGGATCCATCGATTTAAGCATAATC-3’

5’-CCGGTACCCGGAGCCCCAGGATCTC-3’
5’-CGCAGATCTGTCGACCTATTCAGTTTTGCATATCC-3’
5’-CGCAGATCTGGCGCTAGTCATCAC-3’
5’-CCGCAAGCTTGCAACTCATTTCTTC-3’
5’-GATTGAATTCTCTTCCCG-3’

Table 1. List of primers used. Listed are the primers that were used to screen viral
stocks. Also listed are the primers that were used to generate the inducible A30.5
constructs and the knockout plasmids for L2 and A30.5.
Chapter 3: Results
Morphogenesis and Membrane Biogenesis
Morphogenesis is the final stage of the poxvirus lifecycle, and is the process by
which new infectious virions are formed. Unlike many enveloped viruses, vaccinia does
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not form new viral particles though the process of budding. As opposed to budding into or
out of an intracellular membrane-surrounded compartment, the membrane of the vaccinia
virus is generated first as a new entity and grows as it encapsulates core proteins and
genetic material in order to form a mature virion. Much remains to be discovered about
this complex and elusive process.
One of the more mystifying questions that surrounds morphogenesis is membrane
biogenesis, the process by which planar membrane crescents form from the ER
membrane as precursors to the mature virion envelope. Evidence for the ER membrane
as the origin of the crescents comes from localization studies of A14 and A17 along with
knowledge that A14 forms a covalent homo-dimer, an event that can only occur in the ER.
The mechanism of how these membranes are excised from the ER membrane is not
currently known. Classic canonical trafficking pathways have been dismissed through
brefeldin A and dominate negative Sar1 studies.26,

40

Whether this process is

accomplished without cellular proteins remains unknown as well. It is unlikely that the
plethora of proteins involved in biogenesis have been discovered, and it is certain that the
ones that have been identified are not well characterized.
Of the proteins that have been discovered, the F10 kinase is the master regulator
of the process. In F10 ts mutants in non-permissive conditions, crescents do not form and
large electron-dense virosomes do not accumulate. This may not be surprising because
several of the accessory proteins are phosphorylated, as are several of the core proteins
that make up the viroplasm. Phosphorylation by F10 seems to be essential to this process,
however the full scope of kinase activity and how phosphorylation affects its substrates,
viral and cellular, are not currently known. Currently no known phosphorylation events
have been identified as being significant for morphogenesis.
The structural proteins of the membrane crescents are A14, A17, and D13. A14
and A17 are incorporated into the envelope of the mature virion, and no virions are formed
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without them.25, 41 D13 is shed during the maturation process, but is likely responsible for
the shape and stability of the crescents as they grow and change curvature during
immature virion formation and encapsulation.
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Knockouts of any of these structural

proteins results in severe deficits in morphogenesis. 25, 41 24
Lastly, a group of accessory proteins have been identified that are thought to form
a complexe or subcomplexes, and are thought to be essential to membrane biogenesis
and morphogenesis. These proteins include A6, A11, A30.5, H7, and L2 (figure 3). Current
EM studies show a similar phenotype for knockout of these proteins including
accumulation of large electron dense virosomes surrounded by short crescents.27, 34, 42-45
Of these, L2 and A30.5 are transmembrane proteins that are found exclusively in the ER.
It is not known if they function in a singular mechanism of membrane excision, or if they
play different roles in the early stages of membrane biogenesis. Now that they have been
identified, it is crucial to understand the roles of each and begin to characterize them
individually to elucidate the exact roles they play in morphogenesis. Here we aim to
generate the genetic tools necessary to investigate L2 and A30.5’s function, confirm that
these two proteins are in fact essential, and investigate two structural characteristics
known to play a role in the function of other proteins involved in morphogenesis.
GENETIC TOOLS FOR THE STUDY OF A30.5
One of the accessory proteins of membrane biogenesis is A30.5, a small 42-amino
acid protein. A30.5 was once considered to be too small of an open reading frame to
encode a functional protein, but was later identified as an L2-interacting protein and has
been shown to play a role in morphogenesis.34 In fact, an open reading frame similar to to
A30.5 can be found in representatives of all chordopoxvirus genera, suggesting the protein
plays a critical function in the life cycle of the virus.34 A30.5 has a putative transmembrane
domain (figure 5B), and has been shown to insert itself into the ER membrane in a hairpin
fashion with both termini extending into the cytosol (figure4).35 A30.5 is a late post-
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replicative protein, whose expression is inhibited by AraC, an inhibitor of viral DNA
synthesis.34 Immunofluorescence studies have shown A30.5 to co-localize to markers of
the ER and to L2.34 A30.5 was discovered as an L2 interacting protein.34 Knockout studies
have shown that without A30.5 the cell accumulates large electron dense virosomes
surrounded by short crescents that are unable to form immature virions.34
While it is known that A30.5 plays a vital role in membrane biogenesis, little is
known about its structural and functional domains, interactions with other proteins, and
modifications. In order to gain a better understanding of A30.5 we needed to first generate
the genetic tools which could be used to investigate the many questions that still remain
concerning this relatively unknown protein. We decided to construct a virus encoding a
tetracycline-inducible, epitope-tagged A30.5 allele.
As A30.5 has both termini in the cytosol, it was decided that two constructs should
be made, one with a 3xFlag tag on the N-terminal end and one with a V5 tag on the Cterminal end in parallel, in case that one of the tagged alleles failed to complement. The
tagged A30.5’s were cloned so as to have the endogenous promoter preceded by the Tet
operator. The tagged inducible alleles containing the endogenous promoter and a Tet
operator were cloned into a pJS4-TetR vector. A schematic diagram of this strategy is
shown in Figure 6. A remarkable property of the vaccinia virus is its ability to undergo
homologous recombination in the cytoplasm at frequencies high enough to introduce
foreign DNA into the genome of the virus.46 Because of this phenomenon, it is possible to
insert our constructs into a specific locus in the genome. In our system, the genes we want
to insert are flanked by sequences from the non-essential thymidine kinase (TK) gene.
After transfection with our tagged constructs into BSC-40 cells, homologous
recombination occurs at some frequency, and we are left with a pool of wild-type and some
fraction of mutant virions. To select for our mutant, we used TK- cells that only allowed for
replication in mutants lacking the TK gene in the presence of BrDU. When TK is present
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in wild-type virus, BrDU gets phosphorylated and integrates into the genome, disrupting
replication. Through iterative purifications with viral plaques on TK- cells in the presence
of BrDU, we were able to select for a diploid intermediate virus containing endogenous
A30.5 and an inducible tagged A30.5. Induced expression of the tagged A30.5 was
verified by western blot, data not shown.
With our diploid mutants in hand, the next step in the production of an A30.5
inducible virus was to knock out the endogenous allele of A30.5. As before, we used the
virus’ ability to undergo homologous recombination. We generated a plasmid construct
that contain a G418-resistance gene (NEO) flanked by sequences from the genes that
flank A30.5, A30 and A31 (figure 7). To select for the insertion of the cassette and the
replacement of A30.5 with NEO, we selected with G418, an aminoglycoside antibiotic that
blocks peptide synthesis. In the presence of the NEO gene, the viral lifecycle can proceed
in the presence of G418. Through iterative passages of plaques in the presence in G418,
we selected plaques to expand and purify through sucrose gradients to serve as our
stocks for evaluation. They stocks were given the names vindA30.5V5 and
vind3xFlagA30.5.
In order to characterize the utility of our A30.5 inducible viruses, we tested for
expression of tagged A30.5 in viruses during infections performed in the presence or
absence of inducer (tetracycline). Both recombinant viruses expressed A30.5 when
induced, H5 was used as an infection control (figure 8). Unfortunately, we also saw
residual expression in the absence of tetracycline, between 2-11% of what was seen in
the presence of tetracycline (figure 8). Our constructs were found to be leaky, but the
extent that this level of leakiness would have on the virus’ phenotype was not known at
this time.
Further characterization of these viruses included assessing viral yields after a
single round of replication, called a one-step assay. BSC-40 cells were infected at an MOI
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of 3 to ensure every cell in the assay was infected. After eighteen hours, cells were
collected and the viral yield was determined by plaque assay titration. Little difference was
seen between viral yields obtained from induced vindA30.5V5 when compared to wildtype, which was expected; however, there was only a 3-fold difference between induced
and uninduced vindA30.5V5 (figure 9). If the gene was essential for membrane
biogenesis, we would have expected 2-3 log difference. We preformed the same onesteps in HeLa and CV1-CAT cells to confirm the results obtained in BSC-40 cells (figure
9).
In addition to measuring viral yields, another tool to monitor the progression
through the life cycle is to look at the expression of an early protein (I3) and the late protein
(F18) along with the processing of the late protein L4 by the I7 protease. Early blocks in
the life cycle will decrease I3 expression; late blocks affect F18. L4 is a core protein that
gets cleaved by the I7 protease as immature virions are processed. Blocks in
morphogenesis prevent this processing event and serve as a marker for disruptions in this
part of the life cycle. In uninduced mutant viruses, comparable amounts of I3 and F18 are
expressed as compared to wild-type or induced (figure10). L4 processing does change
when the mutants are uninduced, down ~2-fold from permissive conditions (figure 11).
Another property we examined was the size of the plaques after a 48-hour
infection. Twenty plaques were plated in permissive or non-permissive conditions along
with a wild-type control on BSC-40 cells. Under permissive conditions, vindA30.5V5 and
vind3xFlagA30.5 plaques were found to be smaller in total area than wild-type plaques
(figure 12). Under non-permissive conditions, vindA30.5V5 and vind3xFlagA30.5 were
significantly smaller than in permissive conditions (figure 13).
After evaluating the differences between L4 processing and the differences in
plaque size, along with with unchanged viral yields and the leakiness, we saw three
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possibilities: A30.5 is non-essential, the leakiness of vindA30.5V5 and vind3xFlagA30.5
can rescue replication, or our stock is not pure and contains wild-type virus.
To test the purity of our stock we used a PCR assay that took advantage of the
difference in the size of the amplicon that would be generated using primers in the A30
and A31 gene between wild-type’s endogenous A30.5 and vindA30.5V5’s NEO gene. By
using primers that annealed to the flanking A30 and A31 genes, we could resolve two
amplicons, 461bp representing the endogenous A30.5 and 1127bp representing the NEO
insert. Using a dilution of the vindA30.5V5 stock we were able to see the NEO insert, but
did not see an A30.5 insert. In order to test the sensitivity of the assay, we did a mixing
study of vindA30.5V5 and wild-type, where decreasing concentrations of wild-type virus
was mixed into the stock of vindA30.5V5 in order to find the limit of detection. From this
assay we determined that wild-type virus could be detected at a 1:100 wildtype:vindA30.5V5 ratio (figure 14). As we did not see any wild-type amplicon in
vindA30.5V5 alone, we concluded that if there is wild-type virus in our stock, it is less than
1:100. Even if some wild-type virus was present in the stock, the levels are not sufficient
enough to explain the wild-type like viral yields from the single cycle of replication
experiment. This result leaves us with the two other possibilities: A30.5 is non-essential
or low levels of expression are sufficient to rescue the inducible virus.
If A30.5 is non-essential, then it may be possible to construct a knockout mutant
without

being

complemented.

As

was

shown

previously,

vindA30.5V5

and

vind3xFlagA30.5 produced visible plaques in non-permissive conditions, making it
possible to plaque purify an A30.5 knockout, if A30.5 is truly non-essential. As with the
intermediates diploids, wild-type virus underwent homologous recombination after
transfection with a linearized NEO knockout plasmid, knocking out A30.5. Viruses were
selected with G418 and were subject to two rounds of iterative plaque purification. Visual
plaques were identified, although unexpectedly their size was comparable to that of wild-
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type, not the much smaller sizes seen in vindA30.5V5 and vind3xFlagA30.5 in nonpermissive conditions. Several plaques were picked and evaluated via the PCR assay
described above for comparison of the WT and A30.5-deleted locus. Two plaques from
the purification were expanded and purified though a sucrose cushion. Another PCR
mixing study was performed to determine the purity of the stocks. Both purified stocks
were found to be a mix of wild-type and vΔA30.5 (figure 15). This result suggests that
A30.5 may be essential as we were selecting for plaques that originated from a multiple
infection event of wild-type and vΔA30.5, with vΔA30.5 conferring the G418 resistance
and wild-type providing A30.5 needed to form a plaque. While this is only speculation, it
hints that A30.5 may be essential, and can be rescued with low levels of expression.
Knowing that we need to have an A30.5 knockout to see if A30.5 is essential, we
took a different approach to construct the knockout. We decided to generate a
3xFlagA30.5 expressing cell line which in theory should complement a knockout virus,
allowing us to purify a stock free of wild-type. A CV-1 cell system which has the Tet
repressor gene inserted into the genome under selection of blasticidin and a FLP
recombinase recognition target (FRT) site at a common genetic locus was used to
generate an A30.5 cell line (figure 16). Viral genes must undergo codon optimization for
expression in eukaryotic systems to maximize expression and to remove cryptic splice
sites that may interfere with translation. 3xFlagA30.5 was codon optimized by GeneArt
and cloned into a pcDNA5/FRT/TO plasmid containing a CMV promoter and a Tet
operator upstream of 3xFlagA30.5 insert (figure 16). The plasmid also contains an FRT
site and a hygromycin resistance gene. When this construct is co-transfected with plasmid
encoding FLP recombinase, the plasmid containing 3xFlagA30.5 undergoes site-directed
recombination. Over the course of several weeks the cells that underwent the
recombination process were selected for with hyrgomycin and blasticidin. CV1-
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3xFlagA30.5 cells were induced with Dox for 24 hours and screened for 3xFlagA30.5
expression via western. Here we have evidence of a cell line that expresses 3xFlagA30.5
(Figure 17). The ability of this cell line to complement an A30.5 knockout virus remains to
be seen.
Chapter 4: Genetic tools for the study of L2
Among the membrane biogenesis associated proteins, L2 is unique in that it
contains a consensus early promoter and is expressed early in infection.36 It is not known
if L2 plays a role in early infection or if an early role was lost in the evolution of poxviruses.
It is also possible that L2 helps to recruit membrane biogenesis proteins and must be
present before expression of other proteins in order to maintain proper localization and
orientations. L2 is conserved among chordopoxvirus, suggesting it has an essential role
to play in the life cycle.36 Other than its transmembrane domain (figure 5A), L2 does not
have any predicted motifs.36 Like A30.5, L2 is localized to the ER membrane (figure 4),
but is not found in the membrane of mature virions.36 The mechanism of exclusion is not
understood. The absence of L2 has been shown to affect the stability and processing of
several proteins involved in the formation of mature virons.36 Though immune-EM studies,
L2 was found to localize to the edges of growing crescents, which may help to explain
how the planar crescents remain stable in a hydrophobic environment.22 Although L2 is
thought to be essential in membrane biogenesis, it is currently unknown what role L2 plays
and though what mechanism. Further structural and functional analysis of this protein is
needed to further elucidate its mechanism of action.
In order to assess the structure and function of L2 we created a knockout mutant.
As L2 is expressed early in the core of the virion, we are unable to generate a inducible
virus. Early transcription takes place within the virion core using the encapsidated genome
and encapsidated transcriptional machinery that is inaccessible to the Tet repressor. The
generation of a knockout was made possible by the use of a CV1-L2 cell line that was
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constructed previously in our laboratory. The CV1-L2 cell line allows for complementation
and screening of plaques lacking L2 with a reporter gene. As a screening, marker we
chose the fluorescent protein mCherry. A construct was cloned that contained mCherry
flanked by L1 and L3 (figure 18). BSC-40 cells were infected with Wild-type virus and
transfected with the linearized L2-mCherry-L3 plasmid. By homologous recombination,
the mCherry gene was inserted into the genome of the virus. Viruses were plated, allowed
to grow for 48 hours, and screened for fluorescence, at 594 nm absorbance and was
filtered through a Texas Red filter, on induced CV1-L2 cells. mCherry containing plaques
were observed at a low frequency. Fluorescent plaques were isolated and underwent a
round of plaque purification. mCherry expressing plaques were then plated as to isolate
one plaque per well, and passaged four times in this manner. A final plaque was selected,
expanded, and purified through a sucrose cushion to make a stock. The stock was titrated
on induced CV1-L2 cells. A final screen of the stock was performed by plating fifty plaques
to look for the presence of any wild-type, non-fluorescent plaques, none of which were
detected. This virus will be referred to as vΔL2.
To assess the purity of vΔL2 stock further, we performed a western blot analysis
looking for the presence of L2. CV1-L2 cells were infected with either wild-type or vΔL2 in
cells the presence or absence of Dox. In wild-type infection we saw L2 expression,
comparable to that of the expression seen in vΔL2 infection in induced CV1-L2 cells, and
no detectable amounts of L2 was seen in vΔL2 infected in uninduced CV1-L2 (figure 19).
This result suggests that we do indeed have a knockout vΔL2 with a high level of purity.
To characterize the phenotype of the virus we first wanted to look at how well vΔL2
replicated during a single replication cycle compared to wild-type and and in its
complementing cell line. CV1-L2 cells were infected with wild-type virus or vΔL2 with out
without Dox for eighteen hours. Under complementing conditions, vΔL2 replicated to the
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same levels as wild-type. In non-complementing conditions there was a 200-fold decrease
in viral yield compared to vΔL2 grown in complementing CV1-L2 cells (figure 20). We also
tested the ability of vΔL2 to replicate in BSC-40 cells compared to wild-type and saw a
300-fold reduction in viral yield. It was determined that L2 appears to be a gene essential
for viral replication. These results also validate the use of vΔL2 to be used in further
complementation studies.
Unusual for proteins involved in morphogenesis, L2 is expressed early in the
lifecycle of vaccinia. We wanted to understand where the lack of L2 is causing a block in
the lifecycle. We looked at the expression of early (I3) and late (F18) proteins along with
the processing of L4 by the I7 protease. The phenotype of wild-type and vΔL2 in
complementing conditions are similar: I3 and F18 are expressed, and there is a 1:2 ratio
of processed L4 to total L4 expressed (figure 21 and 22). In vΔL2 virus grown in nonpermissive cells, the expression of I3 is similar to wild-type. F18 expression is down by
50%, and the ratio of processed L4 to total L4 is 1:6, where very little is processed (figure
21 and 22). The total L4 expression is down 50% as well when compared to wild-type. No
change in I3 expression suggests that any block in replication is not coming early in
infection. The L4 processing ratio is indicative of a tight block in morphogenesis. The
decrease in the total amount of the late proteins also indicates that the lack of L2 is causing
protein instability or reduced expression as morphogenesis is blocked.
As before, we assayed for plaque size as another phenotype of the vΔL2. Twenty
plaque forming units of wild-type or vΔL2 were absorbed onto permissive or nonpermissive CV1-L2 for 48 hours. Complemented vΔL2 and wild-type virus gave similar
plaque sizes while non-complementing cells infected with vΔL2 produced no visible
plaques (figure 23). This result reinforces the previous results that L2 is an essential gene
and its absence causes a major block in the lifecycle of vaccinia.

25

Chapter 5: Biochemical Characterization Of L2 And A30.5
Dimerization
One consideration for the L2 and A30.5 proteins was the possibility of the formation of
covalent homo- or heterodimers via disulfide bonds. Their proximity to the ER makes them
candidates for the possibility of disulfide bond formation, as the ER is the only organelle
where disulfide bond formation occurs. L2 has a cysteine at position 42, and A30.5 has a
cysteine at position 27. Vaccinia is also thought to contain its own machinery to for
disulfide bonds in the cytosol.47

Another consideration is that the A14 protein, an ER

membrane associated protein that helps to stabilize crescents during membrane
biogenesis, forms a homodimer through a disulfide bond at cysteine 71.48
BSC-40 cells were infected with wild-type virus or vind3xFlagA30.5 and were
harvested at 8 hpi. Cells pellets were lysed in benzonase buffer with benzonase for 30
min at room temperature and were prepared and boiled with loading buffer with or without
β−mercaptoethanol to provide a reducing or non-reducing environment. Samples were
resolved by SDS-PAGE and probed for A14, L2, and 3xFlagA30.5. A14 served as a
positive control since, as mentioned before, it is known to form homodimers. Under nonreducing conditions, dimeric and monomeric forms of A14 can be visualized after SDSPAGE (figure 24). Under reducing conditions, A14 is only seen in its monomeric (nonglycosylated or glycosylated) form. From evidence provided, L2 and A30.5 both resolved
as monomers (figure 24). From the data obtained, it is clear that L2 and A30.5 do not form
covalent homo- or heterodimers.
Phosphorylation
Many proteins involved in morphogenesis are known to be phosphorylated
including A14, A17, F18, and many more.29, 48, 49 The F10 kinase is the master regulator
of morphogenesis, and temperature sensitive mutants with F10 lesions show a complete
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abolition of morphogenesis when grown under non-permissive conditions.50

It is

reasonable to propose that L2 or A30.5 might be phosphorylated as well. L2 has a serine
at position 67 and three threonines at 62, 68, and 84. A30.5 has two serines at positions
5 and 38 and a threonine at position 25.
To test the phosphorylation status of A30.5 and L2, uninfected cells or cells
infected with wild-type virus or vindA30.5V5 were labeled with inorganic 32P to detect any
phosphorylation events and in parallel with
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immunoprecipitations were working properly.

S-methionine in order to verify that the
Cells were lysed in buffer containing

protease and phosphatase inhibitors, and the lysates were immunoprecipitated for F18,
the positive control, L2, and A30.5V5. The proteins were resolved by SDS-PAGE and
subjected to autoradiography. All three proteins were retrieved in the corresponding
immunoprecipitations as shown in the
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S-methionine gel (figure 25). F18 was

phosphorylated (lane 6), as expected. A30.5 was also clearly phosphorylated (lane 4). L2
did not show any phosphorylation signal.
Chapter 6: Discussion
Morphogenesis of poxviruses, and membrane biogenesis specifically, is an elusive
and interesting process whereby a planar membrane is excised from the ER membrane.
Many of the major proteins have been identified including the F10 kinase, the structural
proteins A14, A17, and D13, and the accessory proteins A6, A11, H7, A30.5, and L2.27 It
is possible that this list isn’t completely comprehensive, as other viral and cellular proteins
are possibly implicated in this process. The mechanism of excising a planar membrane is
biologically unique to to poxvirus morphogenesis.27 The holy grail of morphogenesis
research is to know how this is accomplished and how such a unique biological structure
is stabilized in what would intuitively be unfavorable conditions. In order to accomplish this
feat, it is necessary to characterize the members that have already been identified. We
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have decided to focus on two of the accessory proteins and the role they play in membrane
biogenesis.
Several potential roles for the accessory protein complex have been proposed. A
more passive role has been suggested, stating that this group of proteins are responsible
for acting as markers for sites of membrane excision at the ER. Accessory proteins may
be responsible for creating an environment favorable for an unknown mechanism to
produce crescents, or act as recruiter for non-canonical membrane budding mechanisms.
Classical COPII and COPI mechanisms have been dismissed by several, but there is still
an ongoing search for a cellular role in this process.27 Another function of the accessory
proteins may be stabilizing and directing the localization of the crescents as they are
formed to the virosome where they grow and develop into immature virions. Evidence for
this mechanism has come from immuno-EM studies that claim L2 is located at the
periphery of the of the growing crescents, possibly acting as a cap to stabilize what would
be the exposed hydrophobic regions the the end of a planar crescent.22 What is unusual
about the membrane proteins A30.5 and L2 is that they are not integrated to a high degree,
if at all, into the mature virion’s envelope, suggesting the possibility of two mechanisms:
either they are not included in the excised membrane or they are somehow excluded
during the virion maturation process.34, 44 In contrast A14 and A17 also start out as integral
ER membrane proteins and become major components of the mature virus.25
The biggest mysteries surrounding membrane biogenesis is not in the proteins that
are involved but in how this unknown complex breaks the elastic energy that is stored in
the membrane. Not only does this system have to supply the energy needed to break the
crescent free, but it also has to stabilize an open ended planar crescent from folding back
on itself to form a vesicle. In addition, some other mechanism is needed to allow the
stabilized crescents to grow and fuse into larger units, again by some unknown
mechanism, to form a closed membrane surrounding the core proteins and the genome.
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Dynamin is a protein known to break the intermolecular forces of membrane tension during
vesicle formation. This process is thought to be coupled to the hydrolysis of GTP, although
the exact mechanism is not known.51 The reasonable question has to be: is crescent
excision an active process coupled to some source of energy, or is it an energy
independent process driven by remodeling the curvature of the membrane? Several of the
accessory proteins are phosphorylated during infection, and it is possible that this could
provide a source of energy during crescent formation by inducing some conformational
change in the proteins. It is equally possible that the accumulation of viral proteins in the
ER membrane form a lipid raft that distorts the membrane is such a way that it can be
liberated from the ER. There are still theories that crescent formation may still require nonconical cellular excision apparatus, although the question of how the membrane is
ruptured remains the same. Despite all the questions that remain, the most practical way
to begin to answer them is to characterize the proteins that are known to be involved in
membrane biogenesis and morphogenesis to elucidate the role each plays and the
interactions that are involved. Here we set out the generate the genetic tools needed to
study two of the more interesting membrane bound proteins, A30.5 and L2, to validate
their importance in morphogenesis, and to look at some structural aspects of these
proteins.
The A30.5 protein is an ER membrane protein that has been implicated in
morphogenesis. It forms a hydrophobic putative transmembrane domain in the center of
its sequence, and has been shown to form a hairpin structure in the membrane with both
termini exposed to the cytosol.35 A30.5 is a late post-replicative protein that was identified
as an L2 interacting protein.34 Very little is known about its structure or function. A30.5’s
interaction with L2 has not been shown to be direct, and interactions with the rest of the
accessory proteins have not been conducted in detail. It is unknown as to which domains
are important for function. In order to answer these questions, we set out to generate an
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inducible virus that could be used to study the phenotype of the virus without A30.5 and,
to create a system that would allow for complementation assays. Not knowing the
functions of the N- and C-termini, we decided to generate two viruses in parallel with the
thought that one of the two tags might disrupt function and would not complement.
The two A30.5 inducibles that were generated strikingly had much higher viral
yields that expected. Previous research has suggested a much more essential role for
A30.5. As other studies were conducted in other line lines, we thought that A30.5 might
not be necessary in our cell line, so the inducible recombinant was tested in two other cell
types with no significant change in viral yields.
At this time we proposed three possible explanations to investigate: A30.5 is not
essential, low levels of expression are capable of rescuing morphogenesis, or the
presence of contaminating WT virus in our preparations of the inducible recombinant. We
addressed the mixed sample argument with a PCR screen, and we determined that it
wasn’t a contributing factor as no detectible amount of wild-type viruses was ever found.
Knowing that the stocks were pure, we had to contemplate what the low levels of
expression from our leaky constructs meant in context of infection and morphogenesis.
One hypothesis about the accessory proteins is that they work as a stoichiometric entity.
The ability of low levels of A30.5 (<15%) to sustain membrane biogenesis could mean that
the protein acts in a much more transient manner, and isn’t required in high concentrations
when all other proteins are present. Another possibility is that A30.5’s involvement is not
rate limiting in the process of membrane biogenesis. When A30.5 is only present in very
low amounts, it is possible that the decreased production of crescent formation is sufficient
to drive morphogenesis. Contrary to this idea is the decrease in L4 processing that is seen
despite the leaky phenotype, which is not as dramatic as what is seen in the L2 knockout,
but still significant. It is possible that again, we are capturing snapshots of deficits that are
not debilitating or correlated to the final production of infectious virions.
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The next goal was to generate an A30.5 knockout, to test without question if A30.5
was essential in our experimental set-up. First, we attempted to generate a knockout virus
on a non-complementing cell line (BSC40), as our inducible A30.5 viruses produced
macroscopic plaques on this cell line in the absence of inducer. What we observed was a
selection for multiple infection events where wild-type provided A30.5 and vDA30.5
provided resistance. All the plaques that we isolated contained both the knockout and wildtype viruses. The upside to this result was evidence that A30.5 may be essential, however
clear evidence can only be obtained by generating a knockout in a complementing cell
line.

Therefore we generated a cell line that expresses A30.5, allowing for

complementation and removing the selevtive pressure of dual infections. The next major
step will be determining if our cell line is capable of complementing vΔA30.5.
Future studies of this protein include examining the importance of the N- and Cterminal ends of the protein. With a knockout virus, we will be able to generate
complementing plasmid constructs that can be transfected into infected cells. Three
mutants would provide a lot of information about the function of A30.5: an N-terminal
deletion, a C-terminal deletion, and a N- and C-terminal deletion, to look at the importance
of the of the transmembrane domain. Some of the questions we want to ask of these
mutants include what regions are important for membrane biogenesis, what regions affect
localization, what facilitates protein-protein interactions. We already know that A14 is cotranslationally inserted into the membrane of the ER, but it is not known how A30.5 is
localized, whether it post-translationally inserted or if it is like A14 and inserted directly into
the membrane. Also, from our findings, we know that A30.5 is phosphorylated. How that
phosphorylation affects morphogenesis is a significant question. With our A30.5 knockout
virus we will be able to express phospho-null and phosphomimetic mutants to assess the
importance of phosphorylation on function after the sites have been identified. Here we
could perform phosphoamino acid analysis to determine the type of residue that is being
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phosphorylated. Substitution mutants could then be made to identify the specific residue.
Identifying the kinase will also give us some functional insight.
L2, like A30.5, is another ER-membrane bound protein that is part of the accessory
proteins of biogenesis. L2 has two predicted transmembrane domains in its primary
structure with its N-terminus extending into the cytoplasm of the cell.35 Previous research
has implicated L2 as an essential protein of morphogenesis, however very little is known
about its structure and function. What is known is that it localizes with ER marker proteins,
it interacts with A30.5 at some level, and it is essential for the stability of many other
proteins involved in morphogenesis. This is likely due to a higher rate of turnover when
the proteins are not being utilized in the creation of new virions, however the mechanism
of this proteins instability is not fully understood.34, 36 EM studies have shown that in its
absence, large electron dense virosomes form, some with small crescents around their
periphery.44 This phenotype is common in knockout of the accessory proteins. Another
phenomenon has been the identification of L2 at the periphery of the crescents by
immuno-EM, which has been suggested as a capping mechanism for planar crescent
stabilization, however these results have not been entirely conclusive.44 Much remains to
be known about this small yet essential protein.
From these studies, in trying to create the genetic tools with which to study L2, we
have confirmed some important information. Through one-step replication titers we saw a
two-log decrease in vΔL2 compared to vΔL2 in permissive conditions. This is strong
evidence that the virus needs L2 during its lifecycle. Knowing that L2 is expressed early,
we investigated where vΔL2 was causing a block in in the life cycle both early and late.
The expression of the early protein I3 remained constant between vΔL2 in permissive and
non-permissive conditions, suggesting that the block in the lifecycle was not occurring
early. A significant difference was seen when the total total level of expression was
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calculated for the late proteins F18 and L4. This was not surprising as L2 has been
implicated in the stability of morphogenesis proteins. Surprisingly however, this decrease
was only seen in CV1-L2 cells and not in BSC-40 cells. The most striking difference was
the decrease in processing of L4, with an 3-fold decrease compared to complemented
vΔL2.
This result reflects a strong block in morphogenesis. However, it is still odd that
this protein is expressed early, suggesting that L2 might function in some nonessential
role early in infection, had an early role during the evolution of the virus, or it possibly acted
as a beacon for the assembly of membrane biogenesis proteins, in which L2 needs to be
present before they are expressed late in infection. Regardless, here we have shown that
vΔL2 that we produced will be a good genetic tool for further studies of the morphogenesis.
Much as was the case for A30.5, one of the questions that need to be answered
is what domains or residues are important for the function of L2, which can now be
performed with vΔL2 and complementation assays. If L2 is a capping protein, it would be
interesting to see what a tagged construct of its C-terminal end would have on the overall
function of membrane biogenesis. L2’s N-terminus has many clusters of charged residues,
and a cluster charge analysis may also offer insight into regions that are important for
function and for the interactions with other proteins as well as localization. It is not known
how L2 is localized or if it is inserted co-translationally, which in vitro studies may be able
to answer.
The overall goal of our study of membrane biogenesis is to understand how
crescents are excised from the ER and how they are stabilized to allow for crescent growth
and eventually form the IMV membrane. In order to accomplish this, it is going to be
necessary to identify all the proteins that are involved in the process. Furthermore, each
of these proteins is going to need to be characterized individually. The field is only in the
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beginning stages of characterizing the accessory proteins. Their essential role in the
process has been identified, however their role and the mechanisms that they are a part
of are a long way from being elucidated. To complicate these goals, the use of cellular
pathways in membrane biogenesis have not been ruled out. The first step will be to
generate the genetic tools that will allow us to begin to ask these questions, as we have
begun to do with L2 and A30.5. A lofty goal surrounding this research would be the
creation of in vitro system where all the contributors of the mechanism of membrane
biogenesis could be expressed to generate crescents that could be purified and
characterized. As this process is so unusual in biology, it has the potential to further refine
what is known about membrane dynamics.
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Figure 1. Vaccinia Life Cycle. The lifecycle of the poxvirus begins with the entry of the
virion into the host cell. Upon entry, there is expression of early genes within the core,
followed by the uncoating of the virion. Shortly after, replication of the genome along with
the expression of intermediate and late gene products occur. The final step includes
morphogenesis, during which membranes are are diverted from the ER. Proteins and
genetic material from the viroplasm are enclosed, and then mature virions arise after
further processing.
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Figure 2. Morphogenesis. Morphogenesis begins with the diversion of planar membranes
from the ER of the host cell. This process is thought to be orchestrated by the F10 kinase.
Other proteins found to be essential (in blue) are known to associate with the ER
membrane and/or each other and act as accessory proteins in the process of membrane
diversion and enlargement. Structural proteins have also been identified that are crucial
to the process as well (in green and grey). After membrane diversion, the growing crescent
surrounds the virosome and engulf proteins and the DNA genome. Immature virions
undergo various processing events to form mature, infectious virions.
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Figure 3. Accessory proteins of membrane biogenesis. A30.5 and L2 are two of the 5
accessory proteins known to play a role in membrane diversion and morphogenesis. They
are the only ones known to interact with the ER membrane and to interact with each other,
either directly or indirectly. The mechanism by which they facilitate membrane biogenesis
is not known.
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Figure 4. Orientation of L2 and A30.5 in the ER membrane. The topology of L2 and
A30.5 has been determined through split GFP experiments.35 L2’s C-terminus is found
within the ER lumen; it’s N-terminus is exposed in the cytosol. A30.5 forms a hairpin with
both termini exposed within the cytosol.
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A.

L2

B.

A30.5

Figure 5. Hydrophobicity plots. A. L2 is predicted to have two highly conserved
transmembrane domains in the middle of the proteins and one on its C-terminal end. B.
A30.5 is a relatively hydrophobic protein with twenty hydrophobic side chains out of its 42
aa sequence. It contains a putative transmembrane domain between residues 15-33.
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Figure 6. Generation of intermediate A30.5 diploid viruses by homologous
recombination. BSC-40 cells were infected with wild-type virus and transfected with a
plasmid encoding a TET-inducible, epitope-tagged allele of A30.5 under the regulation of
its endogenous promoter; the plasmid directs insertion of the transgene into the nonessential TK locus. This intermediate virus was selected by iterative plaque purification in
the presence of BrDU in TK- cells.
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Figure 7. Generation of endogenous A30.5 knockouts from intermediate diploids by
homologous recombination with NEO. BSC-40 cells were infected with intermediate
diploid viruses and transfected with a plasmid of the structure shown above. In this
plasmid, the NEO gene, which confers resistance to G418, has been inserted in place of
the endogenous A30.5 gene. Upon infection and transfection with a linearized plasmid,
the A30 and A31 flanking regions mediate homologous recombination. The final inducible
recombinants (vind3xFlagA30.5 and vindA30.5V5) were isolated by iterative plaque
purification under G418 selection. The purity of the final virus was confirmed by PCR.

41

Figure 8. Induced expression of 3xFlagA30.5 and A30.5V5 from vind3xFlagA30.5 and
vindA30.5V5. BSC-40 cells were in infected at an MOI of 3 with either wild-type virus,
vind3xFlagA30.5 or vindA30.5V5. Infections were performed in the presence (+) or
absence (-) of TET (1ug/mL) for 18 h. Lysates were then analyzed by immunoblot using
antibodies that recognize the tagged proteins. In the absence of the inducer, residual
expression of the tagged A30.5 proteins was still detected at an average of 11% and 2%,
respectively, over two biological replicates, of the levels seen in the presence of the
inducer. Thus, the viruses are somewhat leaky.
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Figure 9. Single replication cycle viral yields of vindA30.5V5. BSC-40, HeLa, and CV1CAT cells were infected at an MOI of 3 for 18 h with either wild-type virus or vindA30.5V5
under permissive (+TET) or non-permissive (-TET) conditions to allow for one cycle of
replication. Viral yield was then determined (PFU/mL) by titration in BSC40 cells in media
containing TET. In each cell line for three technical replicates, the inducible virus replicated
slightly less well than wild-type virus, and no significant difference at p=0.05 was seen
between permissive and non-permissive conditions as seen in the 3, 6, 14, fold differences
respectively.
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Figure 10. Expression of early and late proteins along with proteolytic processing
during infection with vind3xFlagA30.5 or vindA30.5V5. BSC-40 cells were infected at
an MOI of 3 with either wild-type virus, vind3xFlagA30.5 or vindA30.5V5 in the presence
(+) or absence (-) of TET for 18 h. Lysates were probed for the expression of I3, an early
protein, L4, a late protein that undergoes proteolytic processing during morphogenesis, or
F18, another late protein. All proteins were expressed. A consistent diminution in the levels
of the processed L4 protein were seen when A30.5 expression was reduced, consistent
with a partial impairment of morphogenesis.
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Figure 11. Percent of L4 protein processed compared to total protein during
infection with vind3xFlagA30.5 or vindA30.5V5. BSC-40 cells were infected at an MOI
of 3 with either wild-type virus, vind3xFlagA30.5 or vindA30.5V5 in the presence (+) or
absence (-) of TET for 18 h. Lysates were probed for the expression of processed and
unprocessed L4. Processing was quantified by comparing the total level of L4 protein to
the processed band.
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Figure 12. Plaque sizes of vind3xFlagA30.5 and vindA30.5V5 under permissive and
non-permissive conditions. A monolayer of BSC-40 cells was infected with
approximately twenty pfu of wild-type, vind3xFlagA30.5, or vindA30.5V5 viruses. The
infected cells were incubated for 48h and fixed with crystal violet in formaldehyde solution.
Non-permissive conditions showed a reduction in plaque size for both inducible viruses.
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Figure 13. Plaque area of vind3xFlagA30.5 and vindA30.5V5 in permissive and nonpermissive conditions. A monolayer of BSC-40 cells was infected with approximately
twenty wild-type, vind3xFlagA30.5, or vindA30.5V5 viruses. The infected cells were
incubated for 48h and fixed with crystal violet in formaldehyde solution. Plaque area was
quantified using ImageJ and calibrated to give area in mm2. Non-permissive conditions
showed a 2-fold reduction in plaque size for both inducible viruses, which is significant at
p=0.05.
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Figure 14. Limit of detection assay for stock purity of vindA30.5V5. To test for the
presence of wild-type in the vindA30.5V5 stock, a PCR reaction was used in which the
primers annealed to the A30 and A31 gene. The larger amplicon corresponds to a
template containing NEO resistance (vindA30.5V5); the smaller amplicon corresponds to
the presence of a template containing A30.5 (wild-type). A dilution of 1:50 of the viral
stocks was made for both viruses. Templates included vindA30.5V5 alone, or mixed with
decreasing concentrations of the wild-type dilution. Wild-type amplicon was detectable at
a 1:10-2 mixture, showing any wild-type in the stock would have to be <1:10-2 suggesting
that the purity of the stock is not affecting the characterization of the vindA30.5V5.
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Figure 15. Limit of detection assay for stock purity of ΔA30.5. To test for the presence
of wild-type in the ΔA30.5 stocks, a PCR reaction was used in which the primers annealed
to the A30 and A31 gene. The larger amplicon corresponds to a template containing NEO
resistance (ΔA30.5); the smaller amplicon corresponds to the presence of a template
containing A30.5 (wild-type). A dilution of 1:50 of the viral stocks was made for both
viruses. Templates included ΔA30.5 alone, or mixed with decreasing concentrations of the
wild-type dilution. Wild-type amplicon was detectable at a 1:10-4 mixture, confirming the
sensitivity of the assay. The ΔA30.5 stock reactions amplified both the small and large
amplicon, indicating that the stocks are a mix of ΔA30.5 and wild-type. Primers specific to
the NEO resistance gene were used as a control to detect the presence of ΔA30.5 in the
stocks (lanes #10 and #11).
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Figure 16. Generation of CV1-3xFlagA30.5 cell line. Parent CV1 cells with TetR under
blasticidin selection were transfected with codon optimized 3xFlagA30.5 in
pcDNA5/FRT/TO. 3xFlagA30.5 is under control of the CMV promoter and a Tet operator.
Cells were co-transfected with pOG44 encoding FLP recombinase. Through site-directed
recombination facilitated by FLP recombinase. The resulting cells obtain a single copy of
the transgene encoding an inducible 3xFlagA30.5 allele. Incorporated cells were selected
with hygromycin and maintained in blasticidin.
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Figure 17. Induced expression of 3xFlagA30.5 in CV1 cell line. BSC-40 cells were
infected with vind3xFlagA30.5 at an MOI of 3; cells were collected at 8 hpi. CV13xFlagA30.5 cells were grown to confluency and were left untreated or induced with Dox
[conc] for 24 h. Cell lysates were resolved by SDS-PAGE and subjected to immunoblot
analysis with the M2 anti-FLAG antibody. Under induced conditions 3xFlagA30.5
expression was observed in our cell line, validating it as a genetic tool for the study of
A30.5.
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Figure 18. Generation of L2 knockout by homologous recombination with mCherry.
Prior to isolating an L2-deletion virus, we generated a CV-1 cell line that expresses L2HA
from a single DOX-inducible transgene that is inserted into a common genomic locus in
all cells. BSC-40 cells were then infected with wild-type virus and transfected with a
plasmid that directs the replacement of the L2 gene with the gene encoding the fluorescent
mCherry protein by homologous recombination. vΔL2 was then isolated by iterative
purification of fluorescent plaques on induced CV1-L2HA cells.
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Figure 19. Expression of L2 in CV1-L2 cells infected with vΔL2. CV1-L2 cells were
either left uninduced or induced with DOX for 24 h to induce expression of L2HA. Cells
were then infected with either wild-type virus or vΔL2 at an MOI of 3 for 18 hours. Lysates
were subjected to immunoblot analysis and probed with anti-L2 antibody. No L2 protein
was detected in samples infected with vΔL2 in uninduced cells.
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Figure 20. Viral yields produced by vΔL2 during a single replication cycle. BSC-40
(non-permissive) and CV1-L2 cells (permissive, + DOX; non-permissive, -DOX) were
infected with wild-type virus or vΔL2 at an MOI of 3 for 18 h. Viral yields were then
determined by titration on CV1-L2 cells (+ DOX) (pfu/ml). In induced CV1-L2 cells, vΔL2
replicated as well as wild-type virus. There was an approximately 2-log decrease in vΔL2
yields when infected under non-permissive conditions in CV1-L2 cells. The same >two log
decrease was also seen when the replication of the vΔL2 virus was compared to wild-type
virus in BSC-40 cells.
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Figure 21. Expression of early and late proteins along with proteolytic processing
during infection with vΔL2. CV1-L2 cells were left untreated (-) or treated with DOX for
24 h (+) to induce L2HA expression, and then infected with either wild-type virus or vΔL2
at an MOI of 3 for 18 h. Lysates were probed for the expression of I3, an early protein, L4,
a late protein that undergoes proteolytic processing (*) during morphogenesis, or F18,
another late protein. All proteins were expressed. Little processing of L4 was seen in the
absence of L2, consistent with a tight block in morphogenesis.
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Figure 22. Percent of L4 protein processed compared to total L4 during infection
with vΔL2. CV1-L2 cells were in infected at an MOI of 3 with either wild-type virus or vΔL2
in the presence (+) or absence (-) of Dox for 18 h. Lysates were probed for the expression
of processed and unprocessed L4. Processing was quantified by comparing the
processed L4 as compared to total L4. A significant decreased in processing was seen
suggested a tight block in morphogenesis when L2 is absent.
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Figure 23. Plaque sizes of vΔL2 in permissive and non-permissive conditions. A
monolayer of CV1-L2 cells was treated +/- Dox for 24 h. Cells were infected with
approximately twenty PFU of wild-type virus or vΔL2. The infected cells were incubated
for 48h and fixed with crystal violet in a formaldehyde solution. vΔL2 did not form
macroscopic plaques under non-permissive infections (-DOX).

57

Figure 24. Assay for homodimerization of L2 and A30.5. BSC-40 cells were infected at
an MOI of 3 with wild-type virus or vind3xFlagA30.5 in the presence of Tet. Cells were
collected at 8 hpi. Benzonase-treated whole cell lysates were prepared for SDS-PAGE in
loading buffer with (reducing) or without (non-reducing) β-mercaptoethanol. Lysates were
probed with A14, L2, or Flag antibodies respectively. As expected, A14 shows a clear
dimer band under non-reducing conditions, which disappears when βME is added. L2 and
A30.5 show no clear evidence of dimerization.
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Figure 25. Phosphorylation status of L2 and A30.5. BSC-40 cells were left uninfected
(lanes 1, 3,5,7,9,11) or infected at an MOI of 3 with wild-type virus (lanes 2,6, 8, 12) or
vindA30.5V5 in the presence of TET (lanes, 4,10). The samples to be analyzed for the L2
protein were radiolabeled with 32PPi (lanes 7,8) and with 35S-methionine (lanes 1,2) from
1-4 hpi. Samples to be analyzed for the F18 and A30.5V5 proteins were labeled with PPi
(lanes 9-12) or 35S-methionine (lanes 3-6) from 4-7 hpi. Cell lysates were prepared and
subjected to immunoprecipitation with antibodies directed against L2, F18 or the V5
epitope. Eluants were resolved by SDS-PAGE and visualized by autoradiography and
phosphorimaging. F18, a known phosphoprotein, is present and phosphorylated. A30.5 is
also phosphorylated. L2 appears be be present in the methionine labeling, but show no
noticeable level of phosphorylation.
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